Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 25Leukemia 13Neuroblastoma 12Myelodysplastic Syndromes 12Multiple Myeloma 12Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 8Sarcoma 7Medulloblastoma 7Astrocytoma 7Lymphoma, Non-Hodgkin 6Wilms Tumor 5Osteosarcoma 5Central Nervous System Neoplasms 5Brain Neoplasms 5Sarcoma, Ewing 4Rhabdoid Tumor 4Retinoblastoma 4Optic Nerve Glioma 4Neoplasms 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4Hodgkin Disease 4Hematologic Neoplasms 4Burkitt Lymphoma 4Testicular Neoplasms 3

Interventions

Bortezomib 3filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lenalidomide 2Dexamethasone 2sargramostim 1montanide ISA 51 1merphos 1liposomal doxorubicin 1ixazomib 1itacitinib 1incomplete Freund's adjuvant 1fludarabine phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Plasma Cell × Granulocyte Colony-Stimulating Factor × Clear all
NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡